Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anrikefon vs sufentanil for PONV with PCIA after gynecologic laparoscopy
ChiCTR2600129332Phase 4Not yet recruiting
- Sponsor
- Shanghai First Maternal and Infant Health Hospital
- Start
- Aug 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of hsk21542 in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Shanghai First Maternal and Infant Health Hospital. Primary endpoint: Incidence of postoperative nausea and vomiting at 24 hours postoperatively. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
hsk21542
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2600129332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129332.